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1. E2F-1 transcription factor 
E2F-1 is a transcriptional factor that plays a pivotal role in regulating 
cell-cycle progression by modulaing the timely expression of target genes 
whose products are required for S phase entry, as Cyclin E, and for S 
phase-events, including dihydrofolate reductase (DHFR), thymidine 
kinase (TK), and DNA polymerase α (Pol α). These genes are coordinately 
regulated during the cell growth cycle, being induced in late G1 and S 
phases, at a time when active E2F-1 accumulates. (Müller H et al.  2001; 
Polanger S, Ginsberg D. 2009; Kowalik TF et al. 1995).  
For this reason, E2F-1 transcription activity regulation appears to be 
the most important mechanism controlling cell cycle progression at G1/S 
check-point level and its activity must be tightly regulated in a cell cycle 
phases-dependent manner to allow gene expression to be closely coupled 
with cell-cycle position (Marti A et al. 1999).  
 
1.1 E2Fs family 
E2F-1 belongs to a family of transcriptional factor composed of 8 
proteins (E2F-1 to E2F-8) encoded by distinct genes, overall referred to as 
E2Fs. These factors are central regulators of cell cycle progression 
regulating the timely expression of genes involved in mitosis, 
chromosome segregation, mitotic spindle checkpoints, DNA repair, 
chromatin assembly/condensation, apoptosis, differentiation and 
development. (Kel AE et al. 2001;Mundle SD et al. 2003; Reluca V et al. 
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1997, Wunderlich M and Berberich SJ. 2002). Based on structure and 
function studies, E2F family members have been divided into two main 
subclasses: activator and repressor E2Fs. E2F-1, E2F-2, and E2F-3 are 
potent trans-activators that bind and activate target genes promoters, 
while E2F-4 and E2F-5 are members of the repressor subclass. While 
activator E2Fs expression is timely regulate in response to growth 
stimulation, and their activities peak during G1/S, repressor E2Fs are 
constitutively and during G0 associates in complexes that repress 
transcription of target genes. During G0, both the subclasses associate 
with a class of proteins, “pocket proteins” resulting in their repression or 
activation respectively. Upon re-entry into the cell cycle, pocket proteins 
inactivation results in release of activators E2Fs and disruption of 
repressor complexes. E2F-6, E2F-7, and E2F-8 also contribute to gene 
silencing, but in a manner that is independent of pocket proteins. 
(Timmers C et al. 2007). Overall, E2Fs play a critical role in determining 
the extent and precise timing of target gene expression during cell cycle 
entry via an interesting interplay between repressor and activators 
members. Whereas repression and de-repression appear to be the 
principal mechanism of setting the overall pattern of expression, 
transcriptional activation would serve to accentuate and define the 
precise timing of E2F target expression at the G1-S boundary (Timmers C 
et al. 2007). With the exception of E2F7/8, these transcription factors 
function as heterodimers with members of the DP family (DP1 and DP2), 
1.Introduction 
 
  4 
 
  
with the DNA-binding specificity being determined by the E2F subunit 
(Bell and Ryan, 2004).  
 
1.2 E2F-1 regulation 
Since its crucial role in timely control the cell cycle progression, E2F-1 
is itself tightly controlled by different mechanisms.  Retinoblastoma 
protein binding to E2F-1 regulates its trans-activation activity while E2F-
1 protein levels are regulated both at transcriptional level and by the 
proteasome-dependent degradation pathway. Moreover, there’s evidence 
that human Mouse Double Minute 2 protein (MDM2) binding increases 
E2F-1 stability (Zhang Z et al. 2005). 
 
Activity regulation: pRb-inhibitory binding 
The Retinoblastoma protein (pRb), encoded by RB1 gene, belongs to a 
family of nuclear proteins collectively called pocket proteins that share a 
common structural unit (the pocket) which is critical for protein-protein 
functional interaction (Martelli F et al. 1999). All three pocket proteins 
bind and regulate one or more E2F –DP heterodimers. Among them, pRb 
has largely characterized as tumor suppressor protein for its ability to 
control proliferation by modulating E2F-1 activity. 
During the cell cycle, pRb undergoes a switch active/inactive by 
phosphorylation. In quiescent cells, hypo-phosphorylated (active) pRb 
binds and inhibits E2F-1, preventing its trans-activation, and as a result, 
1.Introduction 
 
  5 
 
  
inhibiting entry in S phase. When the cell is prompt to proliferate, Cyclin 
D increase and bind Cyclin dependent kinases 4 and 6 (Cdk4 and Cdk6), 
to form active complex that progressively phosphorylate pRb, in a 
stepwise manner that subsequently involves also Cyclin E-Cdk2 complex. 
As only the hypo-phosphorylated form of pRb binds and inhibits E2F-1, 
pRb phosphorylation by Cdk4 and Cdk6 complexes, finally results in 
release of free, transcriptional active, E2F-1, allowing to cell-cycle S-
phase entry. (Udayakumar T et al. 2010; Vandel L, Kouzarides T. 1999, 
Mundle SD et al. 2003). (Fig.a). 
 
 
 
 
 
 
 
 
Fig.a Inhibition of E2F-1 transactivation by direct binding of hypo-phosphorylated 
Retinoblastoma protein. The transcriptional ability of E2F is cell cycle-regulated mainly 
through association with the retinoblastoma tumor suppressor proteins (pRb). During 
the cell cycle, pRb undergoes a switch active/inactive by phosphorylation. In quiescent 
cells, hypo-phosphorylated (active) pRb binds and inhibits E2F-1, preventing its 
transactivation. Upon mitogenic stimuli, Cyclin dependent kinases 4 and 6 (Cdk4 and 
Cdk6), each one complexed with Cyclin D, progressively phosphorylate pRb. As only the 
hypo-phosphorylated form of pRb binds and inhibits E2F-1, pRb phosphorylation by 
Cdk4 and Cdk6, results in release of free, transcriptional active, E2F-1, allowing 
expression of genes required for progression into the S phase. 
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Indeed, E2F-1 transactivation activity peaks at G1/S and early S and 
decreases in late S. The importance of the pRb/E2F-1 pathway for normal 
control of cell proliferation is highlighted by evidence that this regulation 
is inactivated in most types of tumor cells (Weinberg, 1995; Dyer and 
Bremner, 2005; Tsantoulis and Gorgoulis, 2005; Burkhart and Sage, 
2008). 
 
Transcriptional regulation 
Another level of regulation of E2F-1 function is reflected by its cell 
cycle-dependent synthesis. There is evidence that the expression of E2F-1 
protein, similarly to other cell cycle regulatory proteins, is closely related 
to the cell cycle phases. In G0 phase, E2F-1 gene expression is barely 
detectable. Upon mitogen stimuli, as cells approach late G1, early 
increasing regulator proteins appear to stimulate E2F-1 transcription 
leading to a progressive accumulation that reach its highest value in S 
phase (Marti et al., 1999, Mundle et al. 2003, Jonson DG et al. 2014). 
Conversely, transcription of the E2F-1 gene decreases in late S and is 
kept at lower level till next cycle began. 
Among positive regulators, cMyc transcriptional factor, D-type Cyclins 
and Cyclin E are reported to modulate E2F-1 expression by activating its 
promoter. Interestingly, E2F-1 itself is described to activate its 
transcription by binding E2F sites within its own promoter (Coller HA et 
al. 2007; O'Donnell KA, 2005; Jonson DG et al. 2014).  
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On the other hand, E2Fs of repressor subclass bind E2F sites and 
keeps target genes transcriptionally repressed in G0 and early G1. At this 
regard, an E2F DNA-binding complex containing the p130 protein and 
one or more repressor E2Fs, have been described to inhibit E2F-1 
transcription by repressing its promoter, and recent experiments suggests 
that pRb does not simply negatively regulates E2F-1 activity but, rather, 
can repress its expression (Jonson DG et al. 2014, Weintraub M et al. 
2002).  
 
Ubiquitin-mediated degradation  
The correct progression through the phases of cell cycle requires a 
strictly temporal control of key regulators so they can in turn, regulate 
the gene expression properly.  
In mammalian cells, ubiquitin-mediated degradation is one among 
most important mechanisms to regulate protein amount, and it is 
particularly used to modulate cell cycle-related transcriptional regulators, 
by rapidly reducing their level when their function is not longer required. 
The process of the ubiquitin-mediate degradation starts with the addition 
of multiple molecules of ubiquitin to target proteins, to produce a poly-
ubiquitin chain tag which is recognized by proteasome machinery as 
signal to destroy the target protein. The poly-ubiquitination reaction is 
carried out in three main steps, activation, conjugation and ligation, and 
requires the coordinate action of three enzymes, each one with a specific 
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function: an ubiquitin-activating enzyme E1, an ubiquitin-conjugating 
enzyme E2 and an ubiquitin-ligase enzyme E3. The high specify of 
ubiquitin-mediate degradation is mediated by E3 enzyme that has a key 
role in substrate recognition.  
Like other key regulators of the cell-cycle, E2F-1 levels are tightly 
regulated by this mechanism. Following its accumulation in the late G1 
phase of the cell cycle, E2F-1 is rapidly degraded in S/G2 phase and is 
kept at low levels until the next G1/S phase transition. This event is 
linked to a specific interaction of E2F-1 with the p45Skp2 (Skp2) 
component of ubiquitin-ligase complex SCFSkp2, which catalyzes E2F-1 
ubiquitination, thus marking it for degradation by the 26S proteasome. 
Disruption of the interaction between E2F-1 and Skp2 results in a 
reduction in E2F-1 ubiquitination leading to stabilization and 
accumulation of transcriptionally active E2F-1 protein (Marti A et al. 
1999; Harper JW and Elledge SJ, 1999). 
 
MDM2 stabilizing binding 
Even if E2F-1 is characterized by high instability, there are evidences 
that Mouse Double Minute 2 protein (MDM2) is able to prolong the half-
life of E2F-1 by inhibiting its proteasome-dependent degradation. In 
facts, in a study of 2005, Zhang Z. et al. have observed that E2F-1 
accumulates upon MDM2 over-expression, while MDM2 inhibition is 
associates with a decrease of E2F-1 protein level. In this study, was then 
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demonstrated that MDM2 directly binds E2F-1 preventing its interaction 
with E3 ligase SCFSkp2 by competition for the same binding site. As a 
result, the attachment of ubiquitin to E2F-1 is inhibited (Zhang Z et al. 
2005). Since the presence of a poly-ubiquitin chain is essential for the 
specific degradation of a protein by the proteasome, MDM2 binding to the 
E2F-1 result in the inhibition of its degradation (Zhang Z et al. 2005). The 
mechanism described above is schematized in figure b.  
 
 
 
 
 
 
 
 
Fig.b Schematic rappresentation of proteasome-dependent degradation of E2F-1 and 
stabilizing function of MDM2. SCFskp2 protein-ligase (SKP2) interacts with E2F-1 and 
catalyzes the addition of ubiquitin molecules (Ub) to form a poly-ubiquitin chain, which 
is the signal for degradation by 26S proteasome. On the contrary, Mouse Double Minute 
2 protein (MDM2) is able to prolong the half-life of the E2F-1. In facts MDM2 binding to 
the E2F-1 protein displace SCFSKP2, protecting the factor from proteasome-dependent 
degradation. 
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1.3 E2F-1 and cancer 
E2F-1 has long been considered an oncoprotein because it has the 
ability to promote quiescent cells to enter S phase and proliferate (Zhang 
Z et al. 2005).  
E2F-1 was originally isolated as the cellular mediator of the 
transforming activity of the product of Adenovirus early region 1A (E1A) 
oncogene. Studies about E2F-1 activation by E1A protein led to elucidate 
the mechanism by which E2F-1 is regulated in normal cells. It was found 
that E1A protein caused pRb dissociation from E2F-1 committing cells in 
late G1 phase to initiate cell cycle progression. This early observation 
that E2F-1 was deregulated by a transforming virus was the first 
indication that E2F may be associated with cancer. It was subsequently 
found that other viral oncoproteins as Simian virus 40 tumor antigen, 
and E7 proteins from 'high-risk' human papilloma viruses, share with 
adenovirus E1A protein the capacity to disrupt the interaction between 
transcription factor E2F-1 and pRb (Chellappan SP et al. 1991; Bell and 
Ryan 2004; Chellappan S et al. 1992; Zhang Z et al. 2005).  
Even if E2F-1 itself is rarely found to be mutated, it is now considered 
that deregulation of E2F-1 is an event in most, if not all, cancers. Given 
the clearly important role played by the pRb/E2F-1 pathway in 
controlling cell growth, it is not surprising that, as well as viral infection, 
a wide spectrum of mutations have been reported to disrupt normal 
function of this pathway. Along with mutation in RB1 gene it-self, that 
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are actually frequent, deregulated expression of D-type Cyclins, Cyclin 
kinase dependent 4 (Cdk4) and p16INK4a Cyclin kinase inhibitor are 
more commonly reported to deregulate the pathway (Nevins JR. 1992). 
Zhan Z. et al. study about the ability of MDM2 to bind and stabilize E2F-
1, suggests that in cells with MDM2 over-expression, the E2F-1 protein 
may be stabilized and kept at a higher level, which may contribute to 
deregulated proliferation and carcinogenesis (Zhang Z et al. 2005). 
Studies using in vitro models, transgenic models with E2F-1 over-
expression and clinical data from patient with different kind of tumor 
have depicted E2F-1 to have a role in oncogenesis, tumor progression and 
therapy resistance (Zhang Z et al. 2005). 
Overall this data underlines the need to further understand pathways 
involved in E2F-1 function and develop new therapies targeting E2F-1. 
2. Aims of the study 
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When a cell is stimulated to proliferate, a series of events occur 
ultimately resulting in release of free active E2F-1, leading to the 
expression of genes that are necessary for entering and progression 
through S phase. Therefore, E2F-1 plays a central role for a cell to 
execute the decision to re-enter cell cycle and proliferate, both in 
homeostatic and pathologic conditions. (Golias CH et al. 2004, Massagué 
J, 2004) 
During recent studies conducted in my laboratory, it was observed that 
experimental ribosomal RNA (rRNA) synthesis inhibition hindered cell 
cycle progression in cells with inactive-p53, by down-regulating E2F-1. It 
was showed that the down-regulation of E2F-1 was due to its increased 
degradation as a consequence of ribosomal proteins interaction with 
MDM2, which inactivated the E2F-1 stabilizing function of MDM2. While 
in p53-proficient cells, the down-regulation of E2F-1 was only of little 
help to p53 in the control of proliferation, in cells with inactive p53, it 
appeared to have a key role in hindering cell proliferation after the 
inhibition of rRNA synthesis (Donati G. et al. 2011). This is, again, in 
keeping with the notion that this protein plays a critical role in 
controlling proliferation, but above all, bring at light a mechanism to 
control cell proliferation independent from p53 activity upon Ribosomal 
biogenesis inhibition. The evidence that the loss of p53 function very 
frequently characterizes human cancers, which are therefore less 
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sensitive to current cytostatic and cytotoxic drug treatment, underlines 
the importance of E2F-1 down-regulation and suggests that E2F-1 
expression may represent a target for therapy of cancers with inactivated 
or deleted p53.  
In this study was experimented a drug combination in order to obtain a 
strong down-regulation of E2F-1 by acting on two different mechanisms 
independent from p53. For this purpose I tested the anti-proliferative 
activity of Nutlin-3a and PD0332991 on a series of cell lines lacking or 
with inactivated p53. 
Nutlin-3a is a selective inhibitor of Mdm2, largely studied for its ability to 
inhibit MDM2-p53 interaction leading to p53 stabilization, and inhibits 
growth in most tumor cells with wild-type p53 (Shen H et al. 2011). 
Worth of note, it has been recently shown that MDM2 direct binding to 
E2F1 prolongs the half-life of E2F1 protecting him from ubiquitination 
(Zhang Z et al., 2005). Since it has been reported that p53 and E2F-1 bind 
to the same region of MDM2 through a well conserved sequence (Marti K 
et al. 2001), I supposed that Nutlin-3a could inhibits also MDM2 binding 
to E2F-1 by interfering with its stabilizing activity and thus leading to 
E2F-1 degradation with the same mechanism described by Donati G. 
(2011). 
In preliminary experiments I found that Nutlin-3a treatment reduced cell 
proliferation rate in TP53-/- and p53-mutated cancer cells as a 
consequence of E2F-1 levels down-regulation, due to its increased 
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degradation. Considering that a sufficient amount of E2F-1 protein was 
left to promote cell cycle progression after Nutlin-3a treatment, I 
expected that the inhibition of pRb phosphorylation should greatly 
increase the Nutlin-induced cytostatic effect by allowing the residual 
E2F-1 amount to be completely linked to hypo-phosphorylated pRb. This 
provided the rationale for testing inhibitors of Cdk4 and Cdk6, in 
combination with Nutlin-3a to obtain a stronger down-regulation of E2F-
1. For this purpose I used Palbociclib (PD 0332991), an oral and selective 
inhibitor of Cdk4 and Cdk6, with ability to block pRb phosphorylation in 
the low nanomolar range, and is in a newly started Phase III clinical trial 
(Rocca A et al. 2014; Web ref. 1). 
As expected, when combined, these drugs strongly hinder cell 
proliferation in p53-/- and p53-mutated cells by blocking them in G1 
phase of cell cycle. 
.  
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3.1 Cell lines, growth conditions and drugs 
The human colon cancer cell line HCT-116, human osteosarcoma Saos-
2 and human osteosarcoma U2OS cell lines were obtained from the 
American Type Culture Collection (ATCC). HCT-116 p53DD cells were 
obtained in my laboratory by viral transduction of a retroviral vector 
expressing a double dominant-negative, truncated form of murine p53 
(Derenzini M et al., 2009). HCT116 p53-/- cell line was kindly provided by 
B. Vogelstein (Johns Hopkins University, Baltimore, MD, USA). All cell 
lines were maintained in DMEM supplemented with 10% fetal bovine 
serum (FBS; Sigma-Aldrich), 2mM L-glutamine (Sigma-Aldrich), 100 
U/mL penicillin and 100 mg/mL streptomycin (Sigma-Aldrich). FBS was 
inactivated by heating to 56° C for 30 min. In addiction HCT-166 p53DD 
were mantained in presence 0.7 µg/ml Puromycin (Sigma-Aldrich) 
selection antibiotic. HCT-116 p53-/- were maintained in presence of 
400µg/ml Geneticin (Sigma-Aldrich) and 100µg/ml Hygromicin B (Sigma-
Aldrich) selection antibiotic.  
All cell lines were cultured in monolayer at 37°C in humidified 
atmosphere containing 5% CO2. When necessary, cells were frozen at -80° 
C in 90% FBS and 10% dimethyl sulfoxide (DMSO, Carlo Erba) and 
stored in liquid nitrogen. 
For each experiment cells were seeded 24h before treatment. 
10 mM working solution of Nutlin-3a (Sigma-Aldrich), PD0332991 
(Pfizer) and MG132 (Sigma-Aldrich) were obtained by dilution in DMSO 
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and administered by dilution in growth media with no selection antibody, 
at final concentrations indicated in Results section. 
 
3.2 Protein extraction and Western Blot 
At the end of the treatment cells were trypsinized and centrifugated at 
7,500 r.p.m, 4°C, for 5 min. to obtain pellets which were stored at -80°C or 
used immediately.  
Cells were vigorously resuspended in lysis buffer [0.1 M KH2PO4 (pH 
7.5), 1% Nonidet P-40 (Sigma-Aldrich) and 0.1 mM β-glycerophosphate 
supplemented prior use with 1X Complete protease inhibitor cocktail 
(Roche Diagnostics), 1mM NaF and 1mM Sodium Orthovanadate] and 
incubated for 30 min on ice. Then samples were centrifuged at 13,000 
rpm, 4°C, for 15 minutes. The cleared supernatants were transferred in 
new tubes and stored at -80°C until use. 
Protein quantification was performed using Bradford assay (Bio-Rad). 
Bovine serum albumin (BSA) was used to design standard curve. Samples 
(30-40 μg of protein) mixed with Leammli loading buffer [10% Glycerol, 
0.2% SDS (Sigma-Aldrich), 1.5 mM Tris, 0.1% Bromophenol Blue, 1.5 M 
β-mercaptoethanol], boiled for 5 min and resolved on 8% or 10% SDS-
PAGE, then transferred to nitro-cellulose membranes (Hybond C Extra, 
Amersham). Filters aspecific binding sites were blocked by incubation 
with 5% non fat powered milk dissolved in TBS-T solution [20 mM Tris, 
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137 mM NaCl, 0.1% Tween 20 (Sigma-Aldrich), pH 7,4] for 1 h at room 
temperature (RT). After washing 3 times for 10 min. RT with TBS-T, 
filters were incubated overnight at 4°C with primary antibodies, diluited 
in 3.5% BSA TBS-T. The following antibodies were used:  
Mouse monoclonal anti-E2F-1 (1:100, KH95, Santa Cruz), mouse 
monoclonal anti-total pRb (1:400, 1F8, NeoMarkers), mouse monoclonal 
anti-phospho pRb (1:200, Ser780, 51B7, NeoMarkers), rabbit polyclonal 
anti-cleaved PARP-1 (1:1000, Cell Signaling) mouse monoclonal anti-total 
MDM2 (1:100, clone 2A10 Calbiochem), rabbit polyclonal anti-phpspho 
MDM2 (1:750, Sigma-Aldrich), mouse monoclonal anti-p53 (1:1000, BP53-
12, Novocastra) and mouse monoclonal anti-β-actin (1:4000, A2228, 
Sigma-Aldrich Chemical Co.). 
The next day filters were washed 3 times for 10 min. RT, incubated 
with the appropriate horseradish peroxidase-conjugated secondary 
antibody (1:10,000 ECL, GE Healthcare) in 5% Milk-TBS-T for 1h at RT, 
and washed again. The horseradish peroxidase activity was detected 
using the appropriate enhanced chemiluminescence substrate (Cyanagen) 
on Hyperfilm enhanced chemiluminescence films (Amersham). 
Densitometric analysis was performed with GelPro analyzer 3.0 (Media 
Cybernetics software). Values were normalized on corresponding ß-Actin 
expression and expressed as fold increase/decrease with respect to 
controls. 
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3.4 Co-immunoprecipitation 
Cells were lysed in Co-IP buffer (50 mM Tris/HCl (pH 8.0), 150 mM 
NaCl, 0.8% Nonidet P-40, 1mM DTT, 1mM EDTA supplemented with 1X 
Complete protease inhibitor cocktail (Roche Diagnostics), 1mM NaF and 
1mM Sodium Orthovanadate) for 30 min on ice and cleared by 
centrifugation at 13,000 r.p.m, at 4°C for 15 min. Whole extracts were 
quantified using Bradford assay (Bio-Rad). Bovine serum albumin (BSA) 
was used to design standard curve. 1.5 mg of proteins for sample, were 
incubated overnight with 4-6 µg/mg of primary rabbit polyclonal anti-
E2F-1 antibody (C-20, Santa Cruz Biotechnology). The next day Protein 
A/G PLUS-Agarose beads (Santa Cruz Biotechnology) were washed in 
Buffer Co-IP, incubated with 5% powdered Milk in Buffer Co-IP for 1h at 
4°C to block aspecific binding sites, washed with Co-IP buffer and 
incubated in equal amount with each sample for 3h at 4°C in agitation, to 
allow them complex the antibody. After centrifugation Immuno-
complexes were washed, resuspended in Leammli and resolved in 10% 
SDS PAGE. Subsequent step and antibody have been previously 
described in “Protein extraction and Western blot” section. 
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3.5  Isolation of total RNA, Reverse Transcription-PCR and Real Time 
PCR 
At the end of the treatment cells were harvested and total RNA was 
extracted with TRI reagent (Ambion, Austin, TX, USA) according to 
manufacturer’s instructions. Extracted RNAs were quantified with a 
Nanodrop spectrophotometer (ND1000) and 2μg of RNA for each sample 
were reverse transcribed using the High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Foster City, CA, USA) as 
recommended by the manufacturer. Real-time PCR analysis was 
performed in a Gene Amp 7000 Sequence Detection System (Applied 
Biosystems) using TaqMan Universal PCR mastermix (Applied 
Biosystems) for the analysis of RB1, TP53, E2F-1, MDM2. Sybr Green 
Universal PCR MasterMix (Applied Biosystems) was used for RRM2 and 
MCM7. Probes were purchased from Applied Biosystems (Assay on 
Demand). Primers were used at a final concentration of 5 μM. 
Primer sequences: 
RRM2 Forward ATCGTCCACCGCAAATGCTTCTA 
RRM2 Reverse AGCCATGCCAATCTCATCTTGTT 
MCM7 Forward ATCGTCCACCGCAAATGCTTCTA 
MCM7 Reverse AGCCATGCCAATCTCATCTTGTT 
 
Experiments were carried out in triplicate for each data point. To 
normalize the expression levels of each gene, TaqMan human-β-
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Glucuronidase (GUS) was used as an endogenous control gene. The 
relative amount of the gene in study was evaluated by the comparative  
2-ΔΔCt method. Briefly: 
ΔCt = Ctgene – CtGUS  
ΔΔCt = ΔCtsample - ΔCtcontrol sample 
2-ΔΔCt = gene expression in sample respect to control 
  
3.6 Crystalviolet assay 
All cells were seeded in duplicate or triplicate in 12-well plates at 
different confluence depending on specific proliferation rate of each cell 
line:  
wt- and p53DD HCT-116   10 • 104 cells/well 
HCT-116 p53-/-     15 • 104 cells/well  
Saos-2       75• 104 cells/well 
The day after plating, Nutlin-3a or Cdk 4/6 inhibitor were added at 
increasing concentrations to generate a dose-response curve. For 
combination treatment Nutlin-3a was used at 10 µM concentration and 
Cdk 4/6 inhibitor at 0.5 µM. An equal amount of vehicle (DMSO) was 
added in control wells. 96h after treatment cells were washed twice with 
PBS and fixed overnight in formalin at 4°C. The day after formalin was 
removed; cells were washed twice with bidistilled water, stained with a 
0.1% w/v crystal violet and 20% v/v methanol water solution for 30 
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minutes in agitation, thus washed 4 times in double-distilled water and 
air dried for 15 min at room temperature. Densitometric quantification of 
crystal violet adsorbed was evaluated by densitometric quantification 
using ChemiDoc system (ChemiDoc XRS, Bio-Rad, Milan, Italy).  
 
3.7 Clonogenic assay 
HCT-116 p53-/- cells were seeded in duplicate in a 6 wells plate at the 
concentration of 250 cells/well in normal medium. After 24h, 10 µM 
Nutlin-3a, 0.5 µM Cdk 4/6 or a combination of both were added at grow 
media and cells were maintained for 9 days at 37°C in humidified 
atmosphere containing 5% CO2. Then cells were fixed in formalin, 
washed once with PBS and stained with a solution of 0,5% crystal violet 
and 25% methanol in water, for 20 min at room temperature. After 
washing and drying, the colonies were counted manually. Results are 
means of three counting reported as fold reduction respect to controls. 
 
3.8 Cell Cycle analysis 
For the cell cycle flow cytometry assay cells were collected 24 h after 
treatment, and fixed in 70% ethanol at 4 °C for 16 h. Fixed cells were then 
washed once with PBS, resuspended in 500 μl PBS containing 10 μg ml−1 
propidium iodide (Life Technologies) and 50 μg ml−1 RNase (Sigma-
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Aldrich) and incubated for 30 min at room temperature in the dark. The 
cells were then centrifuged at 1200 r.p.m. for 5 min, resuspended in 500 μl 
of PBS and analyzed with Fluorescent-Activated Cell Sorter (BD 
FACSaria cell sorter, BD Bioscences, San Jose, CA, USA). FlowJo 
analysis software was used for elaboration of FACS data. 
 
3.9 Statistical analysis 
Student's t test was used to test for statistical significance of the 
differences between the different group parameters.  p values of less than 
0.05 was considered statistically significant. 
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4.1  Nutlin -3a treatment reduces cell proliferation and E2F-1 protein 
level in cells lacking functional p53 protein. 
To study p53-independent effect of Nutlin-3a treatment in human 
cancer cells, I used HCT-116-derived HCT-116 p53-/- cells, in which two 
promoter-less targeting vectors, each containing a geneticin- or 
hygromycin-resistance gene in place of genomic p53 sequences, 
sequentially disrupt the two p53 alleles (Bunz F. et al. 1998), and Saos2 
cell line which are devoid of both TP53 and RB expression (Chen X. et al. 
1996; Wang LH. et al. 1998; Marcellus RC. et al. 1996).  
To evaluate if Nutlin-3a downregulates E2F-1 protein, HCT-116 p53-/-     
cells were treated with increasing doses of Nutlin-3a for 24h, and E2F-1  
protein level was evaluated by Western blot. As expected, Nutlin-3a 
treatment down-regulated E2F-1 protein, and this effect was dose-
dependent. In order to verify if E2F-1 down-regulation observed upon 
Nutlin-3a treatment was due to its increased proteasome-dependent 
degradation this experiment was carried out also in presence of 26S 
proteasome inhibitor MG-132. As shown in figure 1 a, MG-132 
significantly rescued E2F-1 protein level from Nutlin-3a down-regulation 
both at 10µM and 20µM doses, but not when Nutlin-3a is used at 30µM 
concentration, the higher concentration tested. The involvement of 
proteasome was further confirmed by Real Time-RT PCR analysis of E2F-
1 mRNA expression. In fact, consistent with Western blot data, no 
changes were observed in E2F-1 mRNA level, except for samples treated 
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with the higher concentration, demonstrating Nutlin-3a ability to induce 
E2F-1 protein degradation through the ubiquitin-proteasome pathway, in 
a p53-independent manner (Fig. 1 a). 
a)                     b) 
 
 
 
 
 
    
  c)                   d) 
 
 
 
 
 
 
Fig. 1 Nutlin -3a induces E2F-1 proteasomal degradation and hinders cell 
proliferation in cells lacking functional p53 protein (p53-null tumoral cells). a) 
Representative Western blot of E2F-1 protein level in HCT-116 p53-/- cells after 24h 
treatment with increasing doses of Nutlin-3a, in presence or not of 10µM proteasome 
inhibitor MG-132. Cells were exposed to MG-132 for last 2h of Nutlin-3a treatment. b) 
Real time RT-PCR analysis of E2F-1 mRNA in HCT-116 p53-/- cells after 24h of 
treatment with increasing doses of Nutlin-3a. c) Crystal Violet assay and d) 
densitometric quantification in wt-HCT-116, HCT-116 p53-/- and Saos-2 cells after 72h or 
96h respectively of treatment with increasing doses of Nutlin-3a.   
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To investigate p53-independent effects of Nutlin-3a treatment on cell 
proliferation, HCT-116 p53-/- and Saos-2 cells were treated with 
increasing doses of Nutlin-3a and proliferation rate was assessed by 
Crystal Violet staining and densitometric quantification. 
In both cell lines, Nutlin-3a treatment resulted in a significant, dose-
dependent, reduction of cell population, demonstrating that Nutlin-3a is 
able to regulate proliferation through mechanisms independent from p53 
(Fig. 1 c, d). Furthermore, the observation that Crystal violet assay result 
reflects E2F-1 protein reduction revealed on Western blot, strongly 
suggests that Nutlin-3a reduces cell proliferation in p53-null cells down-
regulating E2F-1 protein level.  
Comparable results were obtained using HCT-116 p53DD cells, 
obtained by viral transduction of a retroviral vector expressing a double 
dominant-negative, truncated form of murine p53 (Donati G. et al., 2011). 
In addition HCT-116 and U20S (human osteosarcoma) cells were 
transiently silenced for TP53 by RNA interference. Also in these cells 
Nutlin-3a significantly reduced E2F-1 protein level wile I can’t use them 
for 96h hours Crystal violet proliferation assay because after RNA 
interfering procedure I should wait at least 36-48h to obtain completely 
reduction of p53 protein and start the experiment, but after 96h from the 
end of the silencing procedure p53 start to raise up, giving results not 
completely independent from p53 activity (data not shown).  
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4.2  Cdk 4/6 inhibitor treatment causes a sustained inhibition of pRb 
phosphorylation, suppresses E2F-1 activity and reduce cell 
proliferation in p53-null cells.     
As previously mentioned, it is well known that hypo-phosphorylated 
pRb, but not hyper-phosphorylated pRb, is able to bind E2F-1 and keep it 
inactive. Based on these data a Cdk 4/6 inhibitor  was tested with the aim 
to obtain E2F-1 activity downregulation.  
In order to verify the effect of the inhibitor on Cdk 4/6 activity, HCT-
116 p53-/- cells were treated for 24h with increasing doses of the drug, and 
phosphorylation level of pRb was assessed by Western blot. In both cell 
lines, the treatment significantly reduced pRb phosphorylation, showing 
a dose-dependent trend (Fig. 2, a). Then I performed a time course 
experiment using 1,5 µM Cdk 4/6 Inhibitor,  the concentration that lead to 
an almost complete absence of hypo-phosphorylated pRb, and I found that 
the shorter time-treatment that lead to a strong reduction of 
phosphorylated pRb was 8h. In order to verify if pRb phosphorylation 
reduction, observed after Cdk 4/6 inhibition, increased pRb binding to 
E2F-1, I isolated E2F-1 and associated proteins by Co-
Immunoprecipitation. For this experiment HCT-116 p53-/- cells were 
exposed to 1,5 µM Cdk 4/6 Inhibitor for 8h. Western blot detection of pRb 
in E2F-1 Co-Immunoprecipitate, confirmed that an increased amount of 
pRb binds E2F-1 upon Cdk 4/6 inhibition (Fig. 2, b). This data were 
further confirmed by the reduced transcription of two E2F-1 target genes, 
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Ribonucleotide Reductase-2 (RNR2) and Minichromosome Maintenance 
Complex protein 7 (MCM7), assessed by Real Time RT-PCR analysis after 
8h of treatment. This result demonstrates that E2F-1 transactivation 
activity is significantly reduced in response to Cdk 4/6 inhibitor 
treatment, in HCT-116 p53-/- cells.  
Finally, I investigated the impact of Cdk 4/6 Inhibitor treatment on cell 
proliferation in HCT-116 p53-/-. Crystal violet assay showed that Cdk 4/6 
inhibitor treatment significantly reduces cell population in a dose-
dependent manner. Comparable results were obtained using HCT-116 
p53DD cells (Fig 2, d). 
Taken together, these data suggested that Cdk 4/6 inhibitor affects cell 
proliferation in both p53-null and p53-mutated cells by down-regulating 
E2F-1 activity, through the inhibition of pRb phosphorylation. 
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a)  
 
 
 
 
b)           c)  
 
 
 
  
            d)  
 
 
 
 Fig. 2 Cdk 4/6 inhibitor inhibits cell proliferation in p53-null and p53-muted cells, 
likely down-regulating E2F-1 activity, through the inhibition of pRb phosphorylation.  a) 
Inhibition of pRb phosphorylation at Ser780 on Western blot and densitometric 
quantification. HCT-116 p53-/- cells were treated for 24 hours with increasing doses of 
Cdk 4/6 inhibitor (Cdk 4/6 i). b) Western blot detection of total pRb protein level in E2F-
1 Co-Immunoprecipitate obtained from HCT-116 p53-/- cells treated for 8h with 1,5 µM 
Cdk 4/6 i. 10µM proteasome inhibitor MG-132 was added at last 2h of treatment to avoid 
changes in protein level due to proteasomal degradation. c) Real Time RT-PCR analysis 
of mRNA expression of E2F-1 target genes Ribonucleotide Reductase-2 (RNR2) and 
Minichromosome Maintenance Complex protein 7 (MCM7)  in HCT-116 p53-/- cells after 
8h of 1,5 µM Cdk 4/6 i treatment. Ct mean values of each triplicate were normalized to 
those obtained for β-Glucuronidase and expressed as fold reduction of 2(-
ΔΔCt) values over 
control cells. d) Crystal Violet assay in p53-/- and p53DD HCT-116 exposed for 96h to 
increasing doses of Cdk 4/6 i. 
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4.3  Cdk 4/6 inhibitor-Nutlin-3a drug combination exerts p53-independent  
antiproliferative activity arresting cells in G1. 
To study p53-independent effect of the Cdk 4/6 inhibitor-Nutlin-3a 
combination on proliferation, p53DD and p53-/- HCT-116 cells were 
treated with the two drugs alone, or with a combination of them at the 
same concentrations used for single treatments. Cell proliferation rate 
was analyzed by crystal violet assay. As expected, the combination of the 
two compounds strongly reduce cell population in both p53-null and p53-
muted cell lines (Fig. 3, a). These data were supported by a clonogenic 
assay in p53 -/- that gave comparable result. The clonogenic cell survival 
assay determines the ability of a cell to proliferate indefinitely, thereby 
retaining its reproductive ability to form a large colony or a clone. This 
cell is then said to be clonogenic. In this assay, the treatment with 
combined Cdk 4/6 inhibitor and Nutlin-3a resulted in a significative, 
almost complete, reduction of the number of colonies formed within a 
homogeneous initial cell population (Fig. 3, b). In both Crystal violet and 
Clonogenic assay, treatment with Cdk 4/6 inhibitor and Nutlin-3a 
combination showed a greater inhibitory effect with respect to either 
drug, when used alone (Fig. 3, a and b). 
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   b) 
 
 
 
 
 
Fig. 3 Cdk 4/6 Inhibitor─Nutlin-3a combination treatment hinders cell proliferation 
in both p53-null and p53-muted cell lines. a) Crystal Violet assay after 96h of treatment 
with 0.5 µM Cdk 4/6 inhibitor (Cdk 4/6 i) and 10 µM Nutlin-3a in HCT-116 p53-/- and 
HCT-116 p53DDD cells. b) Clonogenic assay and quantification by counting of colony 
number after 9 days 0.5 µM Cdk 4/6 and 10 µM Nutlin-3a treatment in HCT-116 p53-/-    
. 
  
Next I investigated if the reduction of cell population observed in p53-/- 
and p53DD cells, upon drugs combination treatment, was due to an 
inhibitory activity on cell cycle progression, or to an increased death rate, 
as a result of the activation of apoptotic pathway. To evaluate the effect of 
the treatment on cell cycle progression, HCT-116 p53-/- cells were exposed 
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to Cdk 4/6 inhibitor or to Nutlin-3a or to a combination of both drugs, at 
the same concentrations used for single treatments. After 24h of 
treatment, cells were stained with propidium iodide and cell cycle was 
studied through Flow cytometry. As shown in figure 4, Cdk 4/6 inhibitor 
and Nutlin-3a combination leaded to a significant increase in the 
percentage of cells in G1 phase with a concomitant decline in other 
phases of the cell cycle. Once again, the drug combination showed a 
greater effect with respect to treatment with single drugs (Fig. 4). 
HCT-116 p53-/- 
 
 
 
 
 
 
 
 
 
Fig. 4 Cdk 4/6 inhibitor-Nutlin-3a combination treatment arrest HCT-116 p53-/-cells 
in G1. Flow cytometry analysis of HCT-116 p53-/- cells exposed to 0,5 µM Cdk 4/6 
inhibitor (Cdk 4/6 i) or 10 µM Nutlin-3a or to a combination of both drugs for 24 hours. 
Cells were harvested and fixed as described in Materials and Methods. Flow data 
generated by FACS (Fluorescence Activated Cell Sorting) machine were analyzed by 
FlowJo software to obtain DNA Hystograms and percentage of cells in each phase.  
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Then, to further elucidate mechanisms underlying the reduction of cell 
population observed upon Cdk 4/6 inhibitor-Nutlin-3a combination 
treatment (Fig. 3), I investigated if the treatment exerts a cytotoxic effect 
on cells. Acute response to treatment was evaluated by Cristal violet 
assay. HCT-116 p53-/- were exposed to the treatment for 24h, and then 
were left growing in normal medium for additional 72h. After Crystal 
violet staining, no differences were observed between treated and control 
cells, indicating that the treatment doesn’t induce cell death within 24h. 
By contrast, the same treatment protocol induces a strong reduction of 
cell population in wt-p53 HCT-116 cells, presumably due to the activation 
of apoptotic pathway linked to the presence of functional p53 (Fig. 5, a). 
This hypothesis has been confirmed by Western blot detection of 85-kDa 
fragment of PARP-1, indicator of apoptosis pathway activation (Lazebnik 
Y.A. et al. 1994; Duriez P.J. et al. 1997; Martha A. et al, 2001). In fact, 
after 24h of treatment no changes were observed PARP-1 cleavage in 
HCT-116 p53-/- cells, while it significantly increased in wt-p53 HCT-116, 
accompanied by a strong stabilization of p53 protein (Fig. 5, b). These 
results confirm that Cdk 4/6 inhibitor-Nutlin-3a combination hinders cell 
proliferation in HCT-116 p53-/- arresting cells in G1, and that the 
treatment can induce cytostasis or death depending on p53 status. 
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              b) 
      
 
 
 
 
 
Fig. 5 Cdk 4/6 inhibitor-Nutlin-3a combination act as cytostatic or cytotoxic agent 
depending on p53 status. a) Crystal violet assay and representative scheme of 
sperimental design. wt- and p53-/- HCT-116 cells were treated with a combination of 0.5 
µM Cdk 4/6 inhibitor (Cdk 4/6 i) and 10 µM Nutlin-3a. After 24h the treatment was 
removed and cells were left in normal medium for additional 72h. b) 85-kDa fragment of 
cleaved PARP-1 and p53 protein level by Western blot. wt- and p53-/- HCT-116 cells were 
treated with a combination of 0.5 µM Cdk 4/6 inhibitor and 10 µM Nutlin-3a for 24h. 
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4.4   Cdk 4/6 inhibitor treatment hinders cell proliferation with a pRb-
independent mechanism that induces E2F-1 degradation by 
proteasome machinery, and enhances Nutlin-3a ability to down-
regulate E2F-1 protein level. 
After I demonstrated that Cdk 4/6 inhibitor treatment down-regulates 
E2F-1 activity and hinders cell proliferation in p53-null cells, more 
strongly when combined with Nutlin-3a, I tested Cdk 4/6 inhibitor, alone 
or in combination with Nutlin-3a, on pRb- and p53-null Saos-2 cell line, in 
order to verify that drug effects mentioned above, were the specific 
consequence of pRb phosphorilation inhibition, and thus were dependent 
on the status of pRb. For this purpose, as for HCT-116 p53-/- cells, Saos-2 
cells were exposed to drugs treatment for 96h, and Crystal violet staining 
was used to evaluate the effect on proliferation rate.  
Unexpectedly, also in Saos-2 cells, Cdk 4/6 inhibitor treatment resulted 
in a dose-dependent reduction of cell population, showing a 
synergic/additive effect when combined with Nutlin-3a (Fig. 6, a and b). 
Surprisingly, western blot analysis revealed that Cdk 4/6 inhibitor 
treatment reduces E2F-1 protein level, showing also in this case a 
stronger effect when combined with Nutlin-3a (Fig. 6, c). On the other 
hand, the analysis of Real Time RT-PCR revealed no significant change in 
E2F-1 mRNA levels, upon Cdk 4/6 inhibitor treatment alone or in 
combination with Nutlin-3a (Fig. 6, d). 
These observations drew the conclusion that Cdk 4/6 inhibitor acts not 
only down-regulating E2F1 activity, as initially hypothesized, but also 
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reducing E2F-1 protein level, through such post-transcriptional 
mechanism different from the inhibition of pRb phosphorylation.  
Saos-2 
p53-/-, truncated pRb 
 
 
a) 
 
 
 
     b) 
 
 
 
c)       d) 
 
 
 
 
Fig.6 Cdk 4/6 inhibitor hinders cell proliferation in cells lacking functional pRb 
protein. This effect is stronger when Cdk 4/6 inhibitor is combined with Nutlin-3a. 
Crystal violet assay in Saos-2 cells after 96h of treatment with a) increasing doses of 
Cdk 4/6 inhibitor or b) 0,5 µM Cdk 4/6 inhibitor or 10 µM Nutlin-3a or to a combination 
of both drugs. c) E2F-1 protein level and d) E2F-1 mRNA expression in Saos-2 cells 
treated as in (b). Ct mean values of each triplicate were normalized to those obtained for 
β-Glucuronidase and expressed as fold reduction of 2-ΔΔCt values over control cells. 
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4.5   Cdk 4/6 inhibitor downregulates E2F1 increasing its proteasome-
dependent degradation, likely as a result of a lesser interaction with 
MDM2 
In the second part of the study, I focused my attention on searching the 
possible alternative mechanism by which Cdk 4/6 inhibitor reduces E2F-1 
protein level.  
To investigate if E2F-1 protein reduction was actually due an increased 
degradation by proteasome machinery, I exposed HCT-116 p53-/- cells to 
the drug adding MG-132 proteasome inhibitor at last two hours of 
treatment. As Western blot image in figure 7 shows, MG-132 rescued 
E2F-1 from down-regulation observed upon Cdk 4/6 inhibitor treatment, 
confirming that Cdk4/6 inhibitor increases E2F-1 degradation by 
proteasome 26 S. 
Since data in the literature show that MDM2 is able to bind E2F-1 
protecting him from degradation (Zhang Z et al. 2005), and that the 
down-regulation of MDM2 phosphorylation reduces its protein-protein 
interaction ability (Moll UM. and Petrenko O, 2003) I hypothesized that 
following Cdk 4/6 inhibition a reduction of MDM2 phosphorylation could 
occur, compromising the interaction of MDM2 with E2F-1 with a 
consequent increase in E2F-1 degradation rate. To investigate on this 
idea I carried out a Western blot detection of MDM2 phosphorylation. 
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          p53-/- 
 
 
 
 
  b) 
 
 
 
 
 
b)                    d)  
 
 
 
 
Fig. 7 Cdk 4/6 inhibitor induces E2F-1 and MDM2 protein degradation by the 26S 
proteasome likely by reducing MDM2 phosphorylation. a) Representative Western blot 
detection of E2F-1 level and respective densitometric quantification in HCT-116 p53-/- 
upon 8h of 1,5 µM Cdk 4/6 inhibitor treatment. MG-132 proteasome inhibitor 10 µM was 
added at last 2h of Cdk 4/6 treatment. b) Total and phosphorylated MDM2 protein level 
by Western blot and respective densitometric quantification in p53-/- and p53DD cells 
treated with 1,5 µM Cdk 4/6 inhibitor for 8h. c) Representative western blot detection of 
MDM2 and E2F-1 protein level in HCT-116 p53-/- treated as in (a). d) MDM2 mRNA 
level in HCT-116 p53-/- upon 8h of 1,5 µM Cdk 4/6 inhibitor treatment. Ct mean values 
of each triplicate were normalized to those obtained for β-Glucuronidase and expressed 
as fold reduction of 2-ΔΔCt values over untreated cells. 
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As hypothesized, Western blotting analysis revealed a reduced MDM2 
phosphorylation in treated cells with respect to control cells. To exclude 
that this reduction was due to a reduction of MDM2 protein, I looked also 
to total MDM2 protein level. I found that Cdk 4/6 inhibitor treatment 
reduce total levels of MDM2. To understand which mechanism was 
responsible of MDM2 reduction, I checked mRNA level by Real Time 
RT.PCR, and no significant changes were observed, leading to the 
conclusion that MDM2 protein reduction occurs via a post-transcriptional 
mechanism. These data prompt me to investigate if Cdk 4/6 inhibitor 
causes MDM2 proteasome-dependent degradation. When MG-132 
proteasome inhibitor was added to medium for last two hours of Cdk 4/6 
inhibitor treatment, I didn’t observed any reduction of total MDM2 level 
with respect to control cells.  
Taken together these data indicate that Cdk 4/6 inhibitor increase 
proteasome-dependent degradation of both E2F-1 and MDM2 protein 
through p53-independent mechanism. 
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E2F-1 belongs to the E2F family of transcription factors that are 
situated downstream of growth factor signaling cascades, where they play 
a central role in cell growth and proliferation through their ability to 
regulate genes involved in cell cycle progression (Chen C and Wells AD 
2007). E2F-1 exerts its transcriptional control on cell cycle by regulate the 
timely expression of many target genes whose products are required for S 
phase entry and progression (Müller H et al.  2001; Polanger S, Ginsberg 
D. 2009). For this reason, E2F-1 transcription activity regulation appears 
to be one among the most important mechanisms controlling cell cycle 
progression at G1/S check-point level. 
At this regard, in previous study conducted in my laboratory, it was 
noticed that E2F1 was down-regulated upon inhibition of ribosomal RNA 
synthesis and that this down-regulation slows proliferation rate in p53-
muted cell lines (Donati G, et al. 2011). These results brought to light a 
p53-independent mechanism to control proliferation of tumor cells, 
underling the impact that E2F-1 regulation could have in the control of 
proliferation of tumor that don’t express p53 or harbor p53 mutations 
with complete loss of function. These observations prompt me to 
investigate on mechanisms able to modulate E2F-1 activity, in order to 
obtain a suppression of TP53-/- tumor proliferation. 
It has been demonstrated that MDM2 direct binding to E2F-1 prolongs 
the half-life of E2F1 protecting him from ubiquitination (Zhang Z. et al., 
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Oncogene. 2005). In fact in the study by Donati et al. 2011, it was showed 
that inhibition of MDM2 by binding of ribosomal protein, no longer used 
for ribosome building after rRNA synthesis reduction, down-regulates 
E2F-1 by increasing its proteasomal degradation. Since it has been 
reported that the region of p53, necessary for interaction with MDM2, is 
well conserved in E2F-1, and that both p53 and E2F-1 bind the same 
region of MDM2 (Marti K et al. 2001), I wonder if the MDM2 inhibitor 
Nutlin-3a, that has been extensively demonstrate to inhibit p53-MDM2 
interaction, could reduce also MDM2 binding to E2F-1 and lead to its 
degradation, with the same mechanism previously described (Donati et 
al. 2011). 
In my experiments, Nutlin-3a effectively reduced E2F-1 protein level, 
and this effect was rescued by the proteasome inhibitor MG132 
demonstrating that Nutlin-3a increases E2F-1 degradation by the 26S 
proteasome machinery (Fig. 1 a). Accordingly  no changes where observed 
in E2f-1 mRNA, except when Nutlin-3a was used at 30 µM concentration, 
that is the higher dose tested, at which some additional mechanism likely 
occurred. Moreover, I found that Nutlin-3a inhibits proliferation in both 
HCT-116 p53-/- and p53- / pRb-null Saos-2 cells (Wang LH. et al. 1998; 
Marcellus RC. et al. 1996) showing a dose-dependent trend (Fig. 1 b). The 
fact that this reduction reflected E2F-1 protein reduction rate, let me 
conclude that Nutlin-3a inhibitory effect on proliferation is a consequence 
of E2F-1 down-regulation, which could represent an important 
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mechanism to block proliferation of tumor lacking of functional p53 
protein. My results are in line with study in literature reporting that the 
Mdm2 stabilizing activity on E2F-1 is independent from the status of 
both p53 and pRb (Martin et al. 1995; Xiao et al., 1995). On the contrary, 
Wunderlich M. and Berberich S.J. established that this MDM2 ability 
was mediate by p53, coming to this conclusion through  
experiments involving mutagenesis of Mdm2  in the region involved in 
interaction with p53 (Wunderlich M and Berberich SJ 2002). 
Nevertheless, this MDM2 region is necessary also for its interaction with 
E2F-1 (Martin et al., 2001), thus, maybe, in their experiments 
Wunderlich M. and Berberich S.J disrupted MDM2 interaction not only 
with p53, but also with E2F-1, and this could be one possible explanation 
for these data discrepancy.  
The interaction of pRb with E2F correlates with the capacity of pRb to 
arrest cell growth in G1 phase. Conversely, phosphorylation of the pRb 
protein, mediated by the Gl cyclins and associated Cyclin-dependent 
kinases, inactivates pRb and allows progression through the cell cycle 
(Johnson DG et al. 1994). Considering that in my experiments a sufficient 
amount of E2F-1 protein was left to promote cell proliferation after 
Nutlin-3a treatment, I expected that drug activation of pRb, should 
greatly increase the Nutlin-induced cytostatic effect by allowing the 
residual E2F-1 amount to be completely linked to pRb. Since pRb is active 
only in its hypo-phosphorylated state, its activation can be reached by 
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inhibiting its phosphorylation, and this provided the rationale for testing 
inhibitors of Cdk4 and Cdk6, two Cyclin-dependent kinases that 
associated with Cyclin G1, trigger the massive pRb phosphorylation 
necessary for S phase entry of proliferating cells (ref) 
First I verified the efficacy of the drug on Cdk 4/6 activity by Western 
blot detection of phosphorylated pRb at Serine 780, the pRb residue 
target by Cdk 4/6, in p53-/- cells (Fig 2 a). In line with several study in 
literature, I observed a strong reduction of pRb phosphorylation upon 
Cdk 4/6 inhibitor treatment. Then, I investigate the effect on E2F-1 
activity and I found that after only 8h of treatment Cdk4/6 inhibitor 
increases the amount of pRb bound to E2F-1, and contemporary down-
regulates mRNA expression of two E2F-1 target genes that are necessary 
for entry in S phase of cell cycle. Therefore, as expected, Cdk 4/6 inhibitor 
inhibits E2F-1 trans-activation activity blocking pRb phosphorilation. 
More importantly, Cdk 4/6 reduced HCT-116 p53-/- cells population in a 
dose-dependent way presumably due to E2F-1 down-regulation. These 
data represent a valid rationale to combine Cdk 4/6 inhibitor to Nutlin-3a 
to obtain a drug with strong, p53-independent, anti-proliferative activity 
by targeting two main signaling pathways that regulate E2F-1: 
-   Nutlin-3a: to reduce E2F-1 protein increasing its degradation  
- Cdk 4/6 inhibitor: to down-regulate E2F-1 activity by increasing 
inhibitory binding of pRb  
 
5. Discussion 
 
  
47 
 
  
 
 
 
 
 
 
  
Fig. c. Down-regulation of E2F-1 by a double mechanism. 
 
After I demonstrated the ability of both Nutlin-3a and Cdk 4/6 
inhibitor to hinder cell proliferation through a p53-independent manner, I 
investigated how they affect proliferation when administered together, 
using the lower doses which exhibited an appreciable inhibitory effect in 
single treatments (Fig 1c, d; 2 d). On Crystal violet assay, the treatment 
allowed to a strong reduction of cell proliferation in both p53-/- and 
p53DD cells, thus showing a good efficacy in both p53-muted and p53-null 
tumor cells. Worth of note, when the drugs where administered together 
they inhibit cell proliferation at a greater extent with respect to single 
treatment (Fig. 3 a). Accordingly, flow cytometry analysis showed an 
accumulation of the percentage of single cells in G1 phase, with a 
concomitant decrease of cell number in the other phases. Considering 
that E2F-1 activity is required for expression of proteins necessary for 
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transition from G1 to S phase of cell cycle, this result is consistent with 
the previous results showing the ability of both the drugs to down-
regulate E2F-1. 
In recent years, an increasing number of studies showed E2F-1 dual 
role in controlling both cell growth and apoptosis, and E2F1 mediated 
apoptosis is described to be associated with both p53-dependent and-
independent mechanisms (Saha A et al. 2012; Wu Z et al. 2009; 
Engelmann D et al. 2010; Pediconi N et al. 2003). Moreover, it has been 
showed that Nutlin-3a induces apoptosis in p53-null cell, by activating 
p73 (Ramesh M. et al. 2011). Thus, to further clarify the mechanism by 
which drugs combination reduced cell population in Crystal violet assay, I 
evaluated acute death response and apoptosis pathway activation upon 
drugs combination treatment. After 24h exposure I didn’t observe neither 
cell death, neither activation of apoptotic pathway in p53-/- cells (Fig. 5).  
On the contrary, in wt-p53 HCT-116 cells cell population was strongly 
reduced after 24h treatment, and I observed a significant increase of 85-
kDa fragment of Poly (ADP-Ribose) Polymerase (PARP-1) resulting from 
Caspase cleavage, used as indicator of apoptosis pathway activation 
(Lazebnik Y.A. et al. 1994; Duriez P.J. et al. 1997; Martha A. et al, 2001). 
These results are in line with, and confirm that the Cdk 4/6 inhibitor-
Nutlin-3a combination hinders cell proliferation in HCT-116 p53-/- 
arresting cells in G1, and that the treatment can act as cytostatic or 
cytotoxic agent depending on p53 status. Further supporting this data, 
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western blot analysis showed a strong stabilization of p53 protein 
accompanying the increase PARP-1 cleavage in wt-p53 cells, upon 
combination treatment. 
It has been recognized, through numerous studies, that deficiency in 
pRb is associated with a resistance to Cdk 4/6 inhibition (Lukas J et al. 
1994). Consistent with this phenomenon is the finding that 
pharmacological inhibitors such as PD332991 fail to effect pRb-negative 
tumor cell lines (Rivadeneira DB et al. 2010). 
To specifically define the influence of pRb on the response of p53-null 
cells to Cdk 4/6 inhibition, I used Saos-2 human osteosarcoma cells 
that are devoid of both p53 and pRb expression. Unexpectedly, and 
in contrast with data in literature, Saos-2 cells showed to be just 
a little less susceptible to Cdk 4/6 inhibition, respect to p53-null 
wt-pRb cells. In fact, also in these cells Cdk 4/6 inhibitor reduced 
proliferation in a dose dependent manner, and this effect was 
enhanced by addiction of Nutlin-3a (Fig. 6 a, b). These results are 
consistent with a study where pRb-independent effect of Cdk4/6 
on proliferation where observed in pRb-deficient cell line derived 
from human hepatocarcinoma (Rivadeneira DB et al. 2010), but 
not elucidating mechanism was found to explain this effect. Due 
to the critical role of E2F-1 in cell cycle control, and since all Cdk 
4/6 inhibition effects observed in previous results, where 
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attributed to E2F-1 downregulation, I checked if E2F-1 was 
affected in these pRb-null cells, at both protein and mRNA level. 
Surprisingly, I found that Cdk4/6 inhibitor reduces E2F-1 protein 
level in Saos-2 (Fig. 4) and also in p53-/- and p53-muted HCT-116 
cells (data not shown). This finding let me to reconsider the 
initial hypothesis that Cdk 4/6 effect were mediated only by 
specific inhibition of pRb phosphorylation, and conclude that such 
other mechanism occur to reduce E2F-1 protein level. The fact 
that no changes where observed in E2F-1-mRNA level, let me to 
investigate among post-transcriptional mechanisms of E2F-1 
regulation, and I found that E2F-1 reduction, was due to its 
increased degradation through proteasome pathway.  
Since it is known that MDM2 bind E2F-1 protecting him from 
degradation (Zhang et al. 2005), and it has been reported that 
inhibition of MDM2 phosphorylation reduce MDM2-p53 
interaction (Zhou et al. 2001), we hypothesized that the 
interaction MDM2-E2F1 could be compromised by this 
mechanism following Cdk 4/6 inhibition, leading to a greater 
degradation of E2F-1. As hypothesized, Western blotting analysis 
revealed a reduction in the level of phosphorylation of MDM2 at 
Ser166 and Ser186, that are reported to promotes the nuclear 
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import of Mdm2 and binding to p53 (Feng J. et al. 2004). 
Moreover, Cdk 4/6 inhibition resulted in a reduction of total 
levels of MDM2, and this reduction was canceled by inhibiting 
proteasome. It was in fact reported that phosphorylation of 
Mdm2 by Pkb leads to inhibition of Mdm2 self-ubiquitination and 
stabilization of Mdm2 by protecting him from proteasome-
dependent degradation (Feng J. et al. 2004). Thus, my results 
allowed the hypothesis to be suggested that the inhibitor was 
able to induce E2F-1 proteasome-dependent degradation 
reducing MDM2-stabilisind binding, as a result of a reduced 
MDM2 phosphorylation by Pkb, that in turn increases MDM2 
degradation, thus reducing MDM2 protein level. 
Accordingly with this hypothesis, we found that MDM2 was 
reduced after Cdk 4/6 inhibition, due to its increased degradation 
(Fig. 7 c, d). However, subsequent experiments have shown that 
reduction of the phosphorylation and the levels of MDM2 are not 
tied to a reduced activity of Pkb.  
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The data presented provide evidence that Nutlin-3a-PD0332991 
association could represent a potent anti-proliferative chemotherapeutic 
treatment to block proliferation in cells lacking not only functional p53 
but also lacking functional pRb, by modulating at least two distinct 
mechanisms leading to a synergistic downregulation of E2F-1.  
Consistent with the mechanism described by Donati (2011), my results 
show that the inhibition of MDM2 by Nutlin-3a lead to a down-regulation 
of E2F-1 protein level by increasing its proteasomal degradation, and 
inhibits proliferation in cells lacking functional p53.  
Furthermore, I demonstrated that Cdk4/6 inhibition by PD0332991 
reduces E2F-1 activity by increasing hypo-phosphorylated pRb-E2F-1 
binding, and enhances Nutlin-3a ability to inhibit progression from G1 to 
S phase of cell cycle in p53-null and p53-mutated cells. 
Unexpectedly, I found that PD0332991 reduced proliferation also in cells 
lacking functional pRB, and this effect is stronger when PD0332991 is co-
administered with Nutlin-3a.  This result was explained by the 
observation that PD0332991 not only reduces E2F-1 activity, but also 
reduce E2F-1 levels increasing its degradation. Even if the mechanism by 
which PD0332991 reduce E2F-1 protein level still remains unclear, these 
result suggest that the combined treatment with inhibitors of MDM2 and 
inhibitors of Cdk4/6 may represent a valid chemotherapeutic approach to 
inhibit proliferation in tumors independently of p53 and pRb function.  
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